EMPOWER Trial
Phase 1/2
65
about 6.9 years
18–99
3 sites in CA, FL
About this study
This trial is testing a new treatment called Sarilumab plus Capecitabine in people with triple-negative breast cancer. The goal is to see if it can help eliminate minimal residual disease (MRD) after standard treatments, potentially improving survival and cure rates for this aggressive type of breast cancer.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Capecitabine
- 2.Take Sarilumab 150mg or 200 mg plus Capecitabine
- 3.Take Sarilumab 150mg plus Capecitabine
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
capecitabine, sarilumab, ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
oral (Oral Tablet)
Primary: Phase I: Dose-limiting toxicity (DLT), Phase I: Maximum Tolerated Dose (MTD)
Oncology